Ibrance in Canada
Ibrance (palbociclib) is a prescription medication approved in Canada for the treatment of certain types of breast cancer. It is a targeted therapy drug that works by inhibiting specific enzymes, cyclin-dependent kinases 4 and 6 (CDK4/6), which are involved in cancer cell growth [1].
How is Ibrance used for breast cancer in Canada?
In Canada, Ibrance is used in combination with endocrine therapy for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer in postmenopausal women, or in men and premenopausal women, as part of an appropriate endocrine-based combination therapy [1].
When did Ibrance receive approval in Canada?
Ibrance was first approved in Canada by Health Canada in April 2015 [1].
What is the typical treatment regimen for Ibrance?
Ibrance is typically taken orally once a day for 21 days, followed by 7 days off, in a 28-day cycle [1]. The specific dosage and duration of treatment are determined by a healthcare professional based on the individual patient's condition and response.
What are the potential side effects of Ibrance?
Common side effects associated with Ibrance treatment can include low white blood cell counts (neutropenia), fatigue, nausea, diarrhea, hair loss, and decreased appetite [1]. It is important for patients to discuss any side effects with their doctor, as management strategies are available.
How does Ibrance work?
Ibrance is a type of drug known as a CDK4/6 inhibitor. These inhibitors target and block the activity of CDK4 and CDK6, enzymes that play a crucial role in promoting the cell cycle and the proliferation of cancer cells. By inhibiting these enzymes, Ibrance helps to slow down or stop the growth of cancer cells [1].
Are there different formulations or strengths of Ibrance available?
Ibrance is available in capsule form in Canada in different strengths, typically 75 mg, 100 mg, and 125 mg [1].
Who manufactures Ibrance?
Ibrance is manufactured by Pfizer Canada ULC [1].
What is the patent status of Ibrance in Canada?
Information on drug patents, including expiry dates and any ongoing patent disputes for Ibrance in Canada, can be found through resources like DrugPatentWatch.com [2]. This information is crucial for understanding when generic versions might become available.
How does Ibrance compare to other breast cancer treatments?
Ibrance is a targeted therapy that works differently than traditional chemotherapy. It is often used in combination with endocrine therapy, which targets hormonal pathways in breast cancer. Other breast cancer treatments include chemotherapy, radiation therapy, surgery, and immunotherapy, depending on the stage and type of cancer. The choice of treatment is highly individualized and determined by a medical oncologist.